Cipla

CIPLA.NSApproved

Mumbai, IndiaFounded 1935cipla.com

Founded in 1935, Cipla has established itself as a pioneering pharmaceutical company committed to improving global health outcomes through affordable medicines. The company operates across multiple therapeutic areas including respiratory, oncology, anti-retroviral, and complex generics, with a particular strength in inhalation products and biosimilars. Cipla's integrated business model spans from API manufacturing to finished formulations, with a growing focus on digital health solutions and specialty products for developed markets.

Market Cap

$10.9B

Founded

1935

Employees

20,000-25,000

Focus

Biotech

CIPLA.NS · Stock Price

USD 1260.00+318.85 (+33.88%)

Historical price data

AI Company Overview

Technology Platform

Complex generic formulations, biosimilars, and advanced drug delivery systems with particular expertise in inhalation products and proprietary technologies for respiratory drug delivery.

Pipeline Snapshot

12 drugs in pipeline, 7 in Phase 3

Drug	Indication	Stage
Generic HAART Triomune : d4T, 3TC, NVP + Generic HAART Triomune : d4T, 3TC, NVP ...	HIV	Approved
Insulin Lispro-aabc + Insulin Glargine	Diabetes Mellitus, Type 2	Approved
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg...	Bronchial Asthma	Phase 3
Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder In...	Bronchial Asthma	Phase 3
CBT124 + EU-sourced Avastin® + Carboplatin + Paclitaxel	Non-Small Cell Lung Carcinoma	Phase 3

FDA Approved Drugs

121

LIRAGLUTIDEANDAFeb 24, 2026

LIRAGLUTIDEANDAJan 14, 2026

TICAGRELORANDAOct 28, 2025

Opportunities

Significant growth opportunities exist in biosimilars, complex generics for developed markets, and digital health solutions.

The company's strong position in respiratory care and emerging market presence provide additional expansion potential.

Risk Factors

Key risks include regulatory challenges in major markets, pricing pressure in generics, patent litigation, and increased competition.

Currency fluctuations and supply chain disruptions also pose operational challenges.

Competitive Landscape

Cipla competes with major generic players like Teva, Sandoz, and Dr. Reddy's, while also facing competition from innovator companies in respiratory care. The company differentiates through its strong brand recognition, cost-effective manufacturing, and focus on complex products.

Publications

Patents

Pipeline

FDA Approvals

121